Get email alerts on the Health Policy topic
No spam. Unsubscribe anytime.
Committee clears biomarker testing bill for insurers; first-year state share estimated at $1M
Summary
Senator Delano told the committee SB2694 would require biomarker testing for diagnosis and treatment when supported by scientific evidence and national clinical guidelines; the house passed a similar measure and the committee advanced the bill on a title-sufficient motion.
Senator Delano (Speaker 3) explained SB2694, a bill from the insurance committee that would require insurers to cover biomarker testing used to diagnose, treat and monitor enrolled patients when the testing is supported by medical and scientific evidence and nationally recognized clinical practice guidelines. Delano said the bill is similar to a house measure and named the bill after Representative Casey Yures' wife, Jill, as background to its origin.
Delano told the committee the effective date for policies written under the change would be Sept. 1, 2026, and gave preliminary fiscal estimates: roughly $5.2 million in total costs with an approximate state share of $1,000,000 and some federal funds expected to offset costs. The committee moved the measure forward on a title-sufficient motion and voice vote.
AI generated
The text on this page is AI generated. Summaries, highlights, analysis, and video transcripts are all produced from the original source material.
AI can make mistakes, so if you spot one, and we will fix it for everyone.
Note: the source content is unaltered by us. Any content source we link to, be it a video, an audio recording, or a document, is presented exactly as its publisher released it. That publisher is usually a government body, sometimes an individual official or another organisation.
